Abstract: Objective:The hepatoprotective effects of Ganoderma lucidum peptides (GLP) were researched on Bacille-Calmette-Gu’erin and lipopolysaccharide (BCG/LPS)-induced immunological liver injury in mice. Method:Mice were randomly divided into five groups, namely normal, model and three GLP-treated groups. The mice from model group and GLP-treated groups were treated with BCG from tail vein (iv) on the first day. GLP-treated groups were daily given (ig) the doses of 60, 120 and 180 mg GLP /kg bw respectively. Normal and model groups simultaneously were aiven the same amount of physiological saline for 15 days. Then the mice from model group and GLP-treated groups were treated with LPS (iv). The index of liver and spleen were calculated. AST/ALT activities in serum, MDA,GSH and NO levels and SOD/GSH-Px activity in liver were assayed by the detection kits according to the manufacturer’s protocols. Liver histopathological charactersistics were observed under light microscopy. Results: The index of liver and spleen in mice and ALT/AST activities in serum from the group at high dose are significantly lower than model group’s (p < 0.01). GLP at all of the doses significantly inhibits NO/MDA lever in liver and reduces of SOD/GSH-Px activity and GSH content in liver (p < 0.05～0.01). The liver histopathological characteristics gradually straighten up. At the dose of 180 mg/kg bw GLP, the hepatoprotective effect is the best and the index is close to normal group’s. Conclusion:GLP possesses potent hepatoprotective effects against BCG/LPS-induced liver damage in mice.

Key words: Ganoderma lucidum peptides (GLP)； immunological liver damage； Bacille-Calmette-Gu&rsquo, erin (BCG) lipopolysaccharide(LPS)； hepatoprotective effect；